Dorzolamide

Dorzolamide
Clinical data
Trade names	Trusopt, others
AHFS/Drugs.com	Monograph
MedlinePlus	a602022
Routes of; administration	eye drops
ATC code	S01EC03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Protein binding	~33%
Elimination half-life	4 months
Identifiers
	IUPAC name (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide;
CAS Number	120279-96-1 ; HCl: 130693-82-2 ;
PubChem CID	5284549;
IUPHAR/BPS	6810;
DrugBank	DB00869 ;
ChemSpider	4447604 ;
UNII	9JDX055TW1; HCl: QZO5366EW7 ;
KEGG	D07871 ;
ChEBI	CHEBI:4702 ;
ChEMBL	ChEMBL218490 ;
CompTox Dashboard (EPA)	DTXSID7022960 ;
ECHA InfoCard	100.229.271
Chemical and physical data
Formula	C10H16N2O4S3
Molar mass	324.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCNC1CC(C)S(=O)(=O)c2sc(cc12)S(=O)(=O)N;
	InChI InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1 ; Key:IAVUPMFITXYVAF-XPUUQOCRSA-N ;
	(what is this?) (verify)

Dorzolamide, sold under the brand name Trusopt among others, is a medication used to treat high pressure inside the eye, including in cases of glaucoma.^[3] It is used as an eye drop.^[3] Effects begin within three hours and last for at least eight hours.^[3] It is also available as the combination dorzolamide/timolol.^[3]^[4]

Common side effects include eye discomfort, eye redness, taste changes, and blurry vision.^[3] Serious side effects include Steven Johnson syndrome.^[3] Those allergic to sulfonamides may be allergic to dorzolamide.^[3]^[5] Use is not recommended in pregnancy or breastfeeding.^[5] It is a carbonic anhydrase inhibitor and works by decreasing the production of aqueous humor.^[3]

Dorzolamide was approved for medical use in the United States in 1994.^[3] It is available as a generic medication.^[5] In 2021, it was the 202nd most commonly prescribed medication in the United States, with more than 2 million prescriptions.^[6]^[7]

^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Dorzolamide Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.
^ "Dorzolamide (Ophthalmic Route) Description and Brand Names". Mayo Clinic. Retrieved 3 November 2023.
^ ^a ^b ^c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1148. ISBN 9780857113382.
^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^ "Dorzolamide - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

[1] "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

[2] "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.

[AHFS2019-3] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Dorzolamide Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 March 2019.

[4] "Dorzolamide (Ophthalmic Route) Description and Brand Names". Mayo Clinic. Retrieved 3 November 2023.

[BNF76-5] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1148. ISBN 9780857113382.

[6] "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.

[7] "Dorzolamide - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]